Equity Profile

JNJ

Johnson & Johnson

Health CarePharmaceuticals$560.3B

Jul15Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Johnson & Johnson (JNJ) is a leading health care company that develops pharmaceuticals, medical devices, and consumer health products. With a market cap of $560 billion, it plays a crucial role in the health care sector, focusing on innovation and addressing global health challenges.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$2.84

Revenue

Revenue reflects the overall sales performance and market demand for J&J's products, impacting future growth prospects.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1 2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect J&J to report solid earnings, with a consensus EPS of $2.84 and revenue of $25.0 billion. The market is looking for continued growth in its pharmaceutical segment.

Bull Case

If J&J exceeds EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses EPS or revenue expectations, it may raise concerns about its growth trajectory and impact investor confidence.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$25.0B

Revenue reflects the overall sales performance and market demand for J&J's products, impacting future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will J&J's EPS exceed the consensus estimate of $2.84?

A beat on EPS would reinforce confidence in the company's profitability and growth potential.

What are the revenue expectations for the pharmaceutical segment?

Strong performance in pharmaceuticals is crucial for overall revenue growth and could influence long-term investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate J&J's ability to capitalize on new product launches in its pharmaceutical division, which could drive stronger-than-expected revenue growth.

Supporting Evidence

J&J has a history of exceeding EPS estimates, with a 100% beat rate over the last eight quarters.

The options market is pricing in a larger move than historical averages, indicating heightened expectations for volatility.

Recent insider selling may suggest caution, but it does not necessarily reflect the company's operational performance.

Key Risk

If pharmaceutical revenue comes in below $12 billion, it could challenge the bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on whether J&J can maintain its earnings momentum and address any potential growth challenges.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.70 would confirm the bear case, raising concerns about growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If J&J beats expectations, history suggests a potential stock increase of around 1.22%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of 1.86% following disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·5 sells

Members

House + Senate

Est. Notional

$20,006.00–$125,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key pharmaceutical products.
2Any commentary on cost management and operational efficiencies.
3Insights into market demand and competitive positioning.
4Guidance on future product launches and pipeline developments.
5Management's outlook on macroeconomic factors affecting the health care sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$2.84

Revenue

Revenue reflects the overall sales performance and market demand for J&J's products, impacting future growth prospects.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1 2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect J&J to report solid earnings, with a consensus EPS of $2.84 and revenue of $25.0 billion. The market is looking for continued growth in its pharmaceutical segment.

Bull Case

If J&J exceeds EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses EPS or revenue expectations, it may raise concerns about its growth trajectory and impact investor confidence.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$25.0B

Revenue reflects the overall sales performance and market demand for J&J's products, impacting future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will J&J's EPS exceed the consensus estimate of $2.84?

A beat on EPS would reinforce confidence in the company's profitability and growth potential.

What are the revenue expectations for the pharmaceutical segment?

Strong performance in pharmaceuticals is crucial for overall revenue growth and could influence long-term investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate J&J's ability to capitalize on new product launches in its pharmaceutical division, which could drive stronger-than-expected revenue growth.

Supporting Evidence

J&J has a history of exceeding EPS estimates, with a 100% beat rate over the last eight quarters.

The options market is pricing in a larger move than historical averages, indicating heightened expectations for volatility.

Recent insider selling may suggest caution, but it does not necessarily reflect the company's operational performance.

Key Risk

If pharmaceutical revenue comes in below $12 billion, it could challenge the bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on whether J&J can maintain its earnings momentum and address any potential growth challenges.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.70 would confirm the bear case, raising concerns about growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If J&J beats expectations, history suggests a potential stock increase of around 1.22%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of 1.86% following disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·5 sells

Members

House + Senate

Est. Notional

$20,006.00–$125,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key pharmaceutical products.
2Any commentary on cost management and operational efficiencies.
3Insights into market demand and competitive positioning.
4Guidance on future product launches and pipeline developments.
5Management's outlook on macroeconomic factors affecting the health care sector.